| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Balicatib (also known as AAE-581) is a novel, potent and selective cathepsin K inhibitor that, in cell-based enzyme occupancy assays, has 10-100 times the potency of cathepsin B, L, and S combined. Balicatib inhibited bone turnover at most sites, partially prevented changes in bone mass caused by ovariectomy, and had an unexpected stimulatory effect on periosteal bone formation because it inhibits the osteoclastic enzyme cathepsin K.
| Targets |
cathepsin K (IC50 = 22 nM); cathepsin L (IC50 = 48 nM); Cathepsin B (IC50 = 61 nM); cathepsin S (IC50 = 2900 nM)
|
|---|---|
| ln Vitro |
Balicatib (0-10 µM) exhibits less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 µM in human dermal fibroblasts[2].
|
| ln Vivo |
Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) inhibited bone turnover at most sites, slightly prevented changes in bone mass brought on by ovariectomy, and stimulated the formation of periosteal bone in cynomolgus monkeys[1].
|
| Animal Protocol |
11-13 years, female cynomolgus monkeys (Macaca fascicularis)[1]
0, 3, 10, 50 mg/kg Oral gavage; twice daily for 18 months |
| References | |
| Additional Infomation |
Balicatib has been used in trials studying the treatment of Osteoporosis and Knee Osteoarthritis.
|
| Molecular Formula |
C23H33N5O2
|
|---|---|
| Molecular Weight |
411.5404
|
| Exact Mass |
411.263
|
| Elemental Analysis |
C, 67.12; H, 8.08; N, 17.02; O, 7.78
|
| CAS # |
354813-19-7
|
| Related CAS # |
354813-19-7
|
| PubChem CID |
10201696
|
| Appearance |
white to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
687.4±55.0 °C at 760 mmHg
|
| Flash Point |
369.5±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.590
|
| LogP |
1.56
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
621
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])N([H])C(C1C([H])=C([H])C(=C([H])C=1[H])N1C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C1([H])[H])=O)N([H])C([H])([H])C#N
|
| InChi Key |
LLCRBOWRJOUJAE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
|
| Chemical Name |
N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
|
| Synonyms |
Balicatib; AAE-581; AAE 581; AAE581
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 75~82 mg/mL (182.2~199.3 mM)
Ethanol: ~3 mg/mL (~7.3 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4299 mL | 12.1495 mL | 24.2990 mL | |
| 5 mM | 0.4860 mL | 2.4299 mL | 4.8598 mL | |
| 10 mM | 0.2430 mL | 1.2149 mL | 2.4299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00371670 | Recruiting | Drug: balicatib (AAE581) |
Knee Osteoarthritis | Novartis Pharmaceuticals | December 2004 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA